Filing Flows › Vistagen Therapeutics (VTGN) › Q2 FY26
Vistagen Therapeutics (VTGN) Q2 FY26 earnings results (second quarter fiscal 2026)
10-Q filed Nov 13, 2025
Vistagen Therapeutics (VTGN) reported revenue of $258K for the second quarter fiscal 2026 (Q2 FY26), +41% from a year earlier and +6% from the quarter before.
Vistagen Therapeutics, Q2 FY26: revenue $258K (+41% year over year), net loss $19.4M, operating cash flow −$13.8M. The chart follows the revenue to costs, profit and cash.
| Q2 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $258K | +6% | +41% |
| Operating profit | −$20.1M | — | — |
| Net earnings | −$19.4M | — | — |
| Operating cash flow | −$13.8M | — | — |
What changed
Revenue was $258K in Q2 FY26, up 41% year over year and up 6% from the previous quarter.
Operating costs exceeded revenue by $20.1M, an operating margin of -7772.5%. Total costs grew 41% against revenue growth of 41%. The fastest-growing cost line was Research & development (+56%). The quarter ended with a net loss of $19.4M, wider than the previous quarter's $15.1M loss.
Operating cash flow was −$13.8M. Non-cash charges added back $53K of depreciation and amortization and $1.1M of share-based compensation. Working capital and other items added $4.5M. Capital expenditures of $60K exceeded it, leaving free cash flow of −$13.8M.
Questions
What was Vistagen Therapeutics' revenue in the second quarter fiscal 2026?
Vistagen Therapeutics (VTGN) reported revenue of $258K for the second quarter fiscal 2026 (Q2 FY26), +41% from a year earlier and +6% from the quarter before.